Adjuvant denosumab in early breast-cancer

Giuseppina Campisi, Alberto Bedogni, Vittorio Fusco

Risultato della ricerca: Articlepeer review

Abstract

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Lingua originaleEnglish
pagine (da-a)e124-
Numero di pagine1
RivistaTHE LANCET ONCOLOGY
Volume21
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Entra nei temi di ricerca di 'Adjuvant denosumab in early breast-cancer'. Insieme formano una fingerprint unica.

Cita questo